HUMACYTE INC (HUMA)
NASDAQ • Healthcare
Last close at August 10, 2026 at 20:00 UTC
Fundamentals Charts
About HUMACYTE INC
Humacyte, Inc. (NASDAQ: HUMA) is a healthcare biotechnology company that develops and manufactures implantable human tissues engineered in a laboratory setting. In qualitative terms, it is an early-commercial-stage regenerative-medicine business built around human acellular vessels for vascular repair, reconstruction, and replacement.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
HUMACYTE INC's Technical Indicators Summary
HUMA displays a mixed but overall bearish technical profile with price trading below longer-term averages while short-term averages are supportive, creating a divergence between recent strength and longer-term weakness. Momentum signals are conflicted—stochastic and Williams %R show overbought/sell readings while RSI and MACD sit near neutral—but volatility is notably high by ATR percentage, increasing downside risk on reversals. The OBV reading is deeply negative even as short-term pivots sit near the market, suggesting uneven participation. Technical takeaway: Sell — short-lived strength against weaker longer-term averages and high volatility favor the sell bias.
| Indicator | Value |
|---|---|
RSI (14) | 52.98 |
Stochastic %K (14, 3, 3) | 86.60 |
CCI (20) | 144.86 |
WPR (14) | -4.00 |
Momentum (10) | 0.07 |
MFI | 50.91 |
MACD Level (12, 26) | -0.02 |
Bollinger Bands | $0.60 - $0.75 |
ATR (14) | $0.06 (7.74%) |
ADX (14) | 14.00 |
OBV | -205,518,153 |
Classic Pivot Point | $0.72 |
Fibonacci Pivot Point | $0.72 |
Simple Moving Averages | $0.68 - $1.02(5 indicators) |
Exponential Moving Averages | $0.70 - $1.07(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
HUMA closed the last trading session with a small but positive move, up 3.66% versus the prior day. Kahn Swick & Foti continues to investigate Humacyte's officers and directors, signaling governance risk for HUMA.
Trading Volume
Above 10d avg 2.7M
2.8M
vs S&P 500 Today
Strong Outperformance
+3.72%
52-Week Position
Near lows
9.9%
Updated: August 11, 2026 at 12:26 UTC